Haesuk Park is an associate professor in the Department of Pharmaceutical Outcomes and Policy in the College of Pharmacy. Her research centers on economic and health outcomes studies of medications and pharmaceutical care services as well as policy associated with the use of pharmaceuticals. She is passionate about investigating questions related to health policy in vulnerable populations and, particularly, how a policy affects access to care, the quality and cost of health care, and ultimately health outcomes. In recent years, the clinical focus of Haesuk's research has centered on patients with hepatitis C virus (HCV) infection, a research area with growing intensity and breadth due to the increasing awareness of the disease burden and the continuing development of new treatments.
Areas of Expertise (6)
Claims Data Analysis
Health Services Resaerch
Media Appearances (2)
Dr. Haesuk Park wins Doctoral Dissertation Mentoring Award
UF College of Pharmacy online
Haesuk Park, Ph.D., an associate professor of pharmaceutical outcomes and policy, was selected as the University of Florida College of Pharmacy’s Doctoral Dissertation Mentoring Award winner for 2022. The award recognizes excellence, innovation and effectiveness in mentoring doctoral students throughout their dissertation project.
UF Health researchers use artificial intelligence to better predict hepatitis C treatment outcomes
UF College of Pharmacy online
When hepatitis C treatments fail, patients can face major health risks and the expense of a second therapy. Now, University of Florida Health researchers have developed algorithms that use artificial intelligence to accurately predict when treatment won’t work.
Dosing profiles of concurrent opioid and benzodiazepine use associated with overdose risk among US Medicare beneficiaries: group-based multi-trajectory modelsAddiction
Wei-Hsuan Lo-Ciganic, et al.
One-third of opioid (OPI) overdose deaths involve concurrent benzodiazepine (BZD) use. Little is known about concurrent opioid and benzodiazepine use (OPI–BZD) most associated with overdose risk. We aimed to examine associations between OPI–BZD dose and duration trajectories, and subsequent OPI or BZD overdose in US Medicare.
Comparison of effectiveness and safety for low versus full dose of apixaban during extended phase oral anticoagulation in patients with venous thromboembolismJournal of Internal Medicine
Christina E. DeRemer, et al.
The optimal dose of apixaban therapy to prevent a secondary venous thromboembolism (VTE) event remains unconfirmed. To investigate the effects of extended phase use of apixaban (2.5 vs. 5 mg twice daily) beyond 6 months of initial treatment on the risk of recurrent VTE and major bleeding events among patients with a history of VTE.
Health Care Utilization and Costs Associated With Systemic First-Line Metastatic Melanoma Therapies in the United StatesJCO Oncology Practice
Sascha van Boemmel-Wegmann, et al.
US Food and Drug Administration approvals of immune checkpoint inhibitors and targeted therapies revolutionized the treatment of metastatic melanoma. Our aim was to assess health care resource utilization and costs for patients with metastatic melanoma treated with systemic therapies in first line between January 2012 and December 2017.